Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | B3gnt5 | Rat | (-)-demecolcine | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Demecolcine results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | B3gnt5 | Rat | 17beta-estradiol | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 and PMID:31614463 | B3gnt5 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of B3GNT5 mRNA | CTD | PMID:17101203 | B3gnt5 | Rat | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | B3gnt5 | Rat | 2-butoxyethanol | decreases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | n-butoxyethanol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19812364 | B3gnt5 | Rat | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | B3gnt5 | Rat | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | B3gnt5 | Rat | aflatoxin B1 | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Aflatoxin B1 affects the expression of B3GNT5 protein | CTD | PMID:20106945 | B3gnt5 | Rat | all-trans-retinoic acid | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Tretinoin results in increased expression of B3GNT5 mRNA | CTD | PMID:33167477 | B3gnt5 | Rat | alpha-Zearalanol | increases expression | EXP | | 6480464 | Zeranol results in increased expression of B3GNT5 mRNA | CTD | PMID:35163327 | B3gnt5 | Rat | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of B3GNT5 mRNA | CTD | PMID:16483693 | B3gnt5 | Rat | aristolochic acid A | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of B3GNT5 mRNA | CTD | PMID:33212167 | B3gnt5 | Rat | belinostat | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | belinostat results in decreased expression of B3GNT5 mRNA | CTD | PMID:26272509 | B3gnt5 | Rat | belinostat | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27188386 | B3gnt5 | Rat | benzo[a]pyrene | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of B3GNT5 mRNA | CTD | PMID:22228805 | B3gnt5 | Rat | benzo[b]fluoranthene | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in increased expression of B3GNT5 mRNA | CTD | PMID:26377693 | B3gnt5 | Rat | beta-lapachone | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | beta-lapachone results in decreased expression of B3GNT5 mRNA | CTD | PMID:38218311 | B3gnt5 | Rat | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of B3GNT5 mRNA | CTD | PMID:25181051 | B3gnt5 | Rat | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | B3gnt5 | Rat | bisphenol A | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | bisphenol A results in increased expression of B3GNT5 mRNA | CTD | PMID:38701888 | B3gnt5 | Rat | bisphenol A | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | B3gnt5 | Rat | bisphenol F | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | B3gnt5 | Rat | buta-1,3-diene | decreases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | 1 and 3-butadiene results in decreased expression of B3GNT5 mRNA | CTD | PMID:29038090 | B3gnt5 | Rat | carbon nanotube | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of B3GNT5 mRNA | CTD | PMID:25554681 | B3gnt5 | Rat | chloroprene | decreases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | Chloroprene results in decreased expression of B3GNT5 mRNA | CTD | PMID:23125180 | B3gnt5 | Rat | chlorpyrifos | decreases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of B3GNT5 mRNA | CTD | PMID:37019170 | B3gnt5 | Rat | chlorpyrifos | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of B3GNT5 mRNA | CTD | PMID:34289071 | B3gnt5 | Rat | cisplatin | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Cisplatin results in increased expression of B3GNT5 mRNA | CTD | PMID:27594783 | B3gnt5 | Rat | cisplatin | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27392435 | B3gnt5 | Rat | cisplatin | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of B3GNT5 mRNA | CTD | PMID:27392435 | B3gnt5 | Rat | clorgyline | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Clorgyline results in increased expression of B3GNT5 mRNA | CTD | PMID:19691856 | B3gnt5 | Rat | copper atom | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of B3GNT5 mRNA | CTD | PMID:20971185 | B3gnt5 | Rat | copper(0) | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of B3GNT5 mRNA | CTD | PMID:20971185 | B3gnt5 | Rat | coumestrol | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Coumestrol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | B3gnt5 | Rat | coumestrol | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | B3gnt5 | Rat | crocidolite asbestos | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Asbestos and Crocidolite results in increased expression of B3GNT5 mRNA | CTD | PMID:18687144 | B3gnt5 | Rat | crocidolite asbestos | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Asbestos and Crocidolite affects the expression of B3GNT5 mRNA | CTD | PMID:25757056 | B3gnt5 | Rat | cyclosporin A | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of B3GNT5 mRNA | CTD | PMID:20106945 | B3gnt5 | Rat | dexamethasone | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | B3gnt5 | Rat | Dibutyl phosphate | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | di-n-butylphosphoric acid affects the expression of B3GNT5 mRNA | CTD | PMID:37042841 | B3gnt5 | Rat | dimethylarsinic acid | multiple interactions | ISO | B3gnt5 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | B3gnt5 | Rat | dorsomorphin | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | B3gnt5 | Rat | doxorubicin | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of B3GNT5 mRNA | CTD | PMID:29803840 | B3gnt5 | Rat | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of B3GNT5 mRNA | CTD | PMID:29391264 | B3gnt5 | Rat | Enterolactone | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | B3gnt5 | Rat | entinostat | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | entinostat results in decreased expression of B3GNT5 mRNA | CTD | PMID:26272509 | B3gnt5 | Rat | entinostat | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27188386 | B3gnt5 | Rat | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of B3GNT5 mRNA | CTD | PMID:30307764 | B3gnt5 | Rat | formaldehyde | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Formaldehyde results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 and PMID:27664576 | B3gnt5 | Rat | hydrogen peroxide | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of B3GNT5 mRNA | CTD | PMID:20044591 | B3gnt5 | Rat | indometacin | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | B3gnt5 | Rat | lead(0) | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Lead affects the expression of B3GNT5 mRNA | CTD | PMID:28903495 | B3gnt5 | Rat | melphalan | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Melphalan results in increased expression of B3GNT5 mRNA | CTD | PMID:22363485 | B3gnt5 | Rat | methyl methanesulfonate | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | B3gnt5 | Rat | methylarsonic acid | multiple interactions | ISO | B3gnt5 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | B3gnt5 | Rat | methylisothiazolinone | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of B3GNT5 mRNA | CTD | PMID:31629900 | B3gnt5 | Rat | nickel sulfate | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | nickel sulfate results in increased expression of B3GNT5 mRNA | CTD | PMID:22714537 | B3gnt5 | Rat | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of B3GNT5 mRNA | CTD | PMID:33387578 | B3gnt5 | Rat | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | B3gnt5 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of B3GNT5 mRNA | CTD | PMID:36331819 | B3gnt5 | Rat | phenobarbital | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Phenobarbital affects the expression of B3GNT5 mRNA | CTD | PMID:19159669 | B3gnt5 | Rat | pirinixic acid | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of B3GNT5 mRNA | CTD | PMID:25270620 | B3gnt5 | Rat | potassium chromate | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of B3GNT5 mRNA | CTD | PMID:22714537 | B3gnt5 | Rat | progesterone | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Progesterone results in increased expression of B3GNT5 mRNA | CTD | PMID:21795739 | B3gnt5 | Rat | resveratrol | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | B3gnt5 | Rat | SB 431542 | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | B3gnt5 | Rat | serpentine asbestos | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Asbestos and Serpentine results in increased expression of B3GNT5 mRNA | CTD | PMID:24160326 | B3gnt5 | Rat | silicon dioxide | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of B3GNT5 mRNA | CTD | PMID:25895662 | B3gnt5 | Rat | sodium arsenate | multiple interactions | ISO | B3gnt5 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | B3gnt5 | Rat | sodium arsenite | multiple interactions | ISO | B3gnt5 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | B3gnt5 | Rat | sodium arsenite | increases expression | ISO | B3gnt5 (Mus musculus) | 6480464 | sodium arsenite results in increased expression of B3GNT5 mRNA | CTD | PMID:36209798 | B3gnt5 | Rat | sulforaphane | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | sulforaphane results in increased expression of B3GNT5 mRNA | CTD | PMID:31838189 | B3gnt5 | Rat | sunitinib | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of B3GNT5 mRNA | CTD | PMID:31533062 | B3gnt5 | Rat | toluene | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Toluene results in increased expression of B3GNT5 mRNA | CTD | PMID:28245982 | B3gnt5 | Rat | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of B3GNT5 mRNA | CTD | PMID:25729387 | B3gnt5 | Rat | trichostatin A | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of B3GNT5 mRNA | CTD | PMID:24935251 | B3gnt5 | Rat | triphenyl phosphate | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | triphenyl phosphate affects the expression of B3GNT5 mRNA | CTD | PMID:37042841 | B3gnt5 | Rat | valproic acid | affects expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of B3GNT5 mRNA | CTD | PMID:25979313 | B3gnt5 | Rat | valproic acid | decreases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of B3GNT5 mRNA | CTD | PMID:23179753 more ... | B3gnt5 | Rat | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of B3GNT5 mRNA | CTD | PMID:23034163 | B3gnt5 | Rat | vincristine | increases expression | ISO | B3GNT5 (Homo sapiens) | 6480464 | Vincristine results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | B3gnt5 | Rat | zinc atom | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of B3GNT5 mRNA | CTD | PMID:18593933 | B3gnt5 | Rat | zinc(0) | multiple interactions | ISO | B3GNT5 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of B3GNT5 mRNA | CTD | PMID:18593933 | |